Mary Caffrey

Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression after CAR T-cell therapy, highlighting treatment challenges and outcomes.

Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.

Topline results, to be presented at an upcoming congress, show enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder cancer patients ineligible for cisplatin.

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

Proposed changes to the Physician Fee Schedule aim to support community oncology, but the Inflation Reduction Act threatens financial stability for practices.

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in diffuse large B-cell lymphoma (DLBCL), enhancing precision medicine strategies.

A new survey reveals widespread consumer frustration with prior authorization, highlighting the need for urgent reform in insurance coverage.

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.

CMS Administrator Mehmet Oz, MD, MBA, visited AtlantiCare leaders in Atlantic City, New Jersey, to discuss the need for legislative and regulatory reform, as well as the $50 billion Rural Transformation Program.

ASCO President Robin Zon, MD, FACP, FASCO, emphasizes how AI solutions and advocacy in enhancing cancer care, ensuring equitable access to innovative treatments for all patients.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.

Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and shaping future health care training, as discussed by experts at Tennessee Oncology's “Tech Innovations in Community Oncology."

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."

Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time.

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Coverage from IVBM Princeton, held May 8, 2025.

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.

New Jersey Attorney General Matthew Platkin said the question before the court is whether First Choice Women's Resource Centers can ignore a subpoena amid a state consumer fraud investigation.

A prior settlement of $6 billion was rejected because it would have shielded the Sackler family from lawsuits even from parties who were not part of the agreement.

A global surge in rheumatoid arthritis with local hotspots highlights the need for targeted public health interventions.

Dr Rugo discusses the promising outcomes of trastuzumab deruxtecan for HER2+ breast cancer, addressing interstitial lung disease risks and retreatment strategies.

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.